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http://dx.doi.org/10.1016/j.chembiol.2012.08.006In 2001, the year that scientists first pub-
lished thesequenceof thehumangenome,
the scientific community at large was
amazed simply by the accomplishment
itself. And in the interim 11 years, scientists
worldwide have been churning out tera-
bytes of genomic data at a pace unimagin-
able even just 3 years ago.But now thatwe
all seem to be getting used to the idea
that genome sequencing is mainstream
technology, a new wave of breakthrough
genomic tools are coming along to
help make sense of the pairs of As, Ts,
Cs, and Gs found in the wildly variable
genomes of biological organisms.
Genomic data means little without an
infrastructure, or interpretation platform,While no particular company has emerged as the leader with the
best technology, it is clear that genomic science has moved
beyond the laboratory to the business model.in which to sort it all out. Thanks to
the substantial contributions from com-
putational biologists, mathematicians,
bioinformaticians, computer science
engineers, and a huge variety of other
biological, chemical, and computer spe-
cialists everywhere who have been
immersed in the study of genomic data,
a number of new commercial companies
are stepping forward with genome inter-
pretation platforms and services aimed
at meeting this need.
The need is not strictly academic.
Doctors, hospitals, and patients globally
stand to gain from new tools that can
help health care providers make better
treatment decisions based on a patient’s
genomic status. If companies can de-
velop sufficiently reliable tools for deci-
phering a person’s genome, everyone
has more information about disease pre-
diction, prognosis, and treatment tech-
niques with the best chances for success.
The deluge of genomic data, however,
has resulted in a need for products that
help manage and interpret data froma genome sample. Soon, the cost of
personalized genome testing will not be
prohibitive, but the information challenges
are significant. To meet those challenges,
upward of 200 companies are known to
be working in the genome analysis space.
Though they each offer very different
types of services, it is helpful to place
these business entities into two broad
groups: those that provide interpretive
services on genomic data, such as patient
tumor samples, and those further up-
stream developing the software infor-
matics tools on which interpretation
services are based. While no particular
company has emerged as the leader
with the best technology, it is clear thatgenomic science has moved beyond the
laboratory to the business model.
Personalized Cancer Treatment
Dozens of companies are working toward
providing interpretation of patient geno-
mic data to provide insights related to
potential therapy. For many of these busi-
nesses, their primary focus is oncology
through the assessment of a patient’s
tumor genome for known anomalies or
mutations, with the aim of being helpful
to practicing oncologists. These com-
panies are taking advantage of the
explosion in the understanding of fun-
damental cancer signaling pathways
and essential cancer gene mutations.
Yet even within the cluster of companies
involved with cancer genome interpre-
tation services, the approaches used
vary, as seen in the descriptions of the
following companies.
The technology behind Palo Alto,
California, based GeneKey Corporation
centers on full genome analysis of patient
genes, regardless of whether they haveChemistry & Biology 19, August 24, 2012previously been identified as cancer
related. ‘‘We take a systems biology
approach to find molecular mechanisms
or pathways that appear to be broken,
whether or not those genes are known to
be related to cancer,’’ explains GeneKey
president Raphael Lehrer, Ph.D.
Once GeneKey receives a patient
biopsy, it sends it out to other companies
to do the tumor sequencing and molec-
ular profiling. GeneKey is provided with
information about what genes are mu-
tated and the type of mutation, as well
as information about dysregulation (over-
expression or underexpression of genes
across the full genome). ‘‘From that
information, we are looking to see which
mechanisms appear to be consistently
dysregulated and therefore appear to be
driving the tumor,’’ Lehrer explains. ‘‘We
map that information against known
biology, not just cancer biology, through
extensive analysis of all known gene
databases and sources of gene activity.’’
GeneKey then provides an oncologist
with a report that Lehrer describes as
much like a journal article with dozens of
literature citations. The GeneKey report
may show that a pathway not previously
known to be involved in cancer appears
to be compromised in the tumor sample
due to dysregulation across numerous
genes. The report will also contain litera-
ture citations showing the pathway’s
activity and the therapies that are known
to interact with it, including those in
clinical studies. For example, some pa-
tient analyses have pointed to treatment
with angiotensin receptor blockers—
typically treatments that were off the
oncologist’s radar screen.
Self-described as a high-depth, low-
volume entity, GeneKey was founded
2 years ago and began marketing its
services in December 2010. The cost of
a full genetic analysis runs in the tens of
thousands of dollars and takes several
weeks to complete. Most of the patient
samples assessed thus far have been
for patients who have metastatic, treat-
ment-resistant, or recurrent disease.ª2012 Elsevier Ltd All rights reserved 927
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InnovationsFoundation Medicine, based in
Cambridge, Massachusetts, is working at
the other extreme of genome interpreta-
tion to provide a single ‘‘pan-cancer’’
test to clinicians and oncologists. The
company’s product, known as Foun-
dationOne, offers clinical-grade, next-
generation sequencing to its intended
clientele of clinical specialists and their
patients and also to the company’s
pharmaceutical partners. FoundationOne
is a laboratory-based test, so samples
are sent to the company’s CLIA-certified
lab. FoundationOne analyzes the coding
region of 182 cancer-related genes and
37 introns in 14 genes frequently rear-
ranged in human cancer. ‘‘We focus on
the subset of the genome unequivocally
implicated in cancer,’’ says Vincent Miller,
M.D., Senior Vice President of Clinical
Development at Foundation Medicine,
who explains that the test simultaneously
uncovers all classes of DNA alterations
including base substitutions, small inser-
tions/deletions, copy number alterations
(including homozygous deletions), and
gene rearrangements. Miller explains that
by sequencing the entire coding region
of genes of relevance, their test identifies
anomalies that may not be anticipated
but could be relevant to decision-making
for the treating physician.
‘‘Each aspect of our test is geared to
making it applicable to a doctor working
in an oncology practice in the commu-
nity,’’ explains Miller. To this end, the test
is designed to be effective using small-
tissue specimens (40 mm or more of
formalin-fixed, paraffin-embedded tissue,
which roughly translates into 50 ng of
DNA), suboptimal sample procurement,
and heterogeneous tumor samples,
which can sometimes contain more than
80% noncancer content. ‘‘By testing the
same group of 182 genes plus those
involved in rearrangements regardless
of tumor site of origin and providing a
straight-forward interpretive report, this
text makes genomic information clinically
useful for doctors who are in a tsunami
of molecular information,’’ he adds.
Founded in April 2010, Foundation
Medicine is now a 60+ person venture.
FoundationOne received CLIA approval
late in 2011 and was formally launched
at the ASCO June 2012. In the six months
from CLIA certification to ASCO, Founda-
tion Medicine had received more than
400 clinical cases.928 Chemistry & Biology 19, August 24, 2012Genome Interpretation Software
Platforms
Nearly 100 companies—and counting—
are developing software-based products
to serve research scientists by taking
the raw data and turning it into a form
that a scientist/researcher can use to
analyze data. Their customers include
pharmaceutical companies, research
institutes, academic labs, and other geno-
mics companies.
Station X is one of the newest entrants
into this realm of genomic analysis.
Founded in late 2010, the goal of this
Redwood City, California, based com-
pany is to develop software its clients
can use to discover and validate bio-
markers inclinicalR&D. ‘‘Weareaplatform
for next-generation sequencing analysis
with a particular bent on clinical and
translational research—helping people
who are using large scale genome infor-
mation, whether it be transcriptome,
whole genome, or exome—discover, vali-
date, and turn new markers into clinically
relevant markers,’’ says Richard Goold,
Ph.D., cofounder and Station X CEO.
Working closely with one of its in-
vestors, Genomic Health, Station X has
built its GenePool product to help re-
searchers conduct primary translational
clinical research by analyzing and visu-
alizing large-scale genomic data, in-
cluding genome cohorts. ‘‘Our partner-
ship with Genomic Health has given us
access to real-world genomic data and
experts to develop our platform,’’ adds
Tod Klingler, Ph.D., cofounder and chief
scientific officer. GenePool is designed
to operate with multiple sequencing
platforms.
Cancer is also the first focus for Station
X’s technology, but they plan on devel-
oping genomic software tools to enable
discovery and validation of the causes
of rare inherited diseases. Named after
the location where World War II Allied
cryptographers operated, Station X re-
cently secured its series B funding
to advance its genetic code-cracking
services.
Cambridge,Massachusetts-basedKnome
is seeking to operate in both the world
of software development and clinical
genome interpretation. Boldly marketing
itself as the ‘‘human genome interpreta-
tion company,’’ Knome started life as an
interpretation services provider. Its first
client was the third person in the worldª2012 Elsevier Ltd All rights reservedto have his genome commercially
sequenced. Since then, Knome has
branched out into the interpretation world
by leveraging its platform services base.
Knome’s software tools have been
aimed toward academic researchers,
primarily cancer researchers, who are
assessing the genetic basis of diseases,
as well as pharmaceutical companies
who want to use genomic information to
determine the patient population for a
particular drug. Starting with one research
institution, the 75 person company now
collaborates with a dozen pharmaceutical
companies and two dozen research insti-
tutions, including the National Cancer
Institute and Johns Hopkins.
Within weeks, the company expects
to launch a clinical version of its software
called knomeCLINIC. ‘‘We’re outfitting
medical researchers with a clinically
tailored enterprise version of the whole
genome interpretation platform that our
scientists use in-house for academic
clients,’’ explains Nathaniel Pearson,
Ph.D., director of research at Knome.
‘‘Doing so brings key tools to clinics, who
can rarely afford to develop their own
platforms, to help them interpret whole
genomes at scale.’’ Knome does not act
as the testing laboratory directly. Instead,
the program delivers software medical
institutions can use to make better deci-
sions based on genomic data.
Clinically, Knome aims to service
the cancer marketplace and to help
detect the source of unknown genetic
diseases—a reason why Knome finds
that cancer institutes and children’s
hospitals are among the first adopters of
translated genomic data. ‘‘The big impact
is going to be when you have the whole
genome, you can run all the genetic tests
you want in software,’’ adds Jonas Lee,
chief marketing officer at Knome. ‘‘It takes
clicks in software to run tests, not days or
weeks in a wet lab. You will soon be able
to run complex panels on hundreds of
genes in seconds—it will be fast, and it
will be cheap.’’
Clearly, this is an area of genome
science that will enjoy explosive growth
in the next decade, which will hopefully
push the breadth and pace of pharmaceu-
tical discovery and personalized patient
care.Alice McCarthy (alice@alicemccarthy.com) is a
science writer based in Gloucester, Massachusetts.
